NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at Stifel Nicolaus

Research analysts at Stifel Nicolaus started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $44.00 price target on the stock. Stifel Nicolaus’ price target points to a potential upside of 118.25% from the stock’s current price.

Several other brokerages also recently weighed in on NAMS. Scotiabank upped their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Thursday, February 27th. Needham & Company LLC cut their price target on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, May 8th. Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an “overweight” rating and a $42.00 price objective for the company. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Friday, May 30th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.00.

NewAmsterdam Pharma Stock Up 0.1%

NAMS stock opened at $20.16 on Tuesday. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29. The firm has a market cap of $2.26 billion, a P/E ratio of -10.72 and a beta of -0.03. The company’s 50-day simple moving average is $17.82 and its 200-day simple moving average is $20.86.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). The company had revenue of $2.98 million during the quarter, compared to the consensus estimate of $1.46 million. On average, analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director James N. Topper acquired 1,135 shares of the firm’s stock in a transaction on Wednesday, March 26th. The shares were bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the acquisition, the director now owns 3,013,569 shares of the company’s stock, valued at approximately $67,775,166.81. This trade represents a 0.04% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 20.84% of the stock is owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Large investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of NewAmsterdam Pharma by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock worth $5,898,000 after buying an additional 34,563 shares in the last quarter. Woodline Partners LP raised its holdings in NewAmsterdam Pharma by 0.5% in the 1st quarter. Woodline Partners LP now owns 2,442,397 shares of the company’s stock valued at $49,996,000 after acquiring an additional 11,615 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in NewAmsterdam Pharma by 32.6% in the 1st quarter. Parkman Healthcare Partners LLC now owns 100,955 shares of the company’s stock worth $2,067,000 after purchasing an additional 24,839 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in NewAmsterdam Pharma in the 1st quarter worth approximately $610,000. Finally, Duquesne Family Office LLC boosted its holdings in shares of NewAmsterdam Pharma by 178.4% during the 1st quarter. Duquesne Family Office LLC now owns 800,360 shares of the company’s stock worth $16,383,000 after purchasing an additional 512,825 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.